[go: up one dir, main page]

PE20020216A1 - PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS - Google Patents

PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS

Info

Publication number
PE20020216A1
PE20020216A1 PE2001000584A PE2001000584A PE20020216A1 PE 20020216 A1 PE20020216 A1 PE 20020216A1 PE 2001000584 A PE2001000584 A PE 2001000584A PE 2001000584 A PE2001000584 A PE 2001000584A PE 20020216 A1 PE20020216 A1 PE 20020216A1
Authority
PE
Peru
Prior art keywords
alkyl
refers
nucleoside
aryl
substituted
Prior art date
Application number
PE2001000584A
Other languages
English (en)
Inventor
Martin L Bryant
Jean-Louis Imbach
Gilles Gosselin
Original Assignee
Idenix Cayman Ltd
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Cayman Ltd, Centre Nat Rech Scient filed Critical Idenix Cayman Ltd
Publication of PE20020216A1 publication Critical patent/PE20020216A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A PRODROGAS 3' DE 2' DESOXI-ß-L-NUCLEOSIDOS DONDE EL TERMINO 2'- DESOXI SE REFIERE A UN NUCLEOSIDO QUE NO TIENE SUSTITUYENTES EN POSICION 2' Y EL TERMINO PRODROGA 3' SE REFIERE A UN DESOXI-ß-L-NUCLEOSIDO QUE TIENE UNA PORCION SEPARABLE EN LA POSICION 3' INCLUYENDO ACILO Y UN L-AMINOACIDO. SE REFIERE A UN ß-L NUCLEOSIDO 3'-O-SUSTITUIDO DE FORMULA I DONDE R1 ES H, ALQUILO, CO-ALQUILO, CO-ARILO, CO-ALCOXIALQUILO, ENTRE OTROS; R2 ES ALQUILO, CO-ALQUILO, CO-ARILO, CO-ALCOXIALQUILO, CO-ARILOXIALQUILO, ENTRE OTROS; X ES O, S, SO2, CH2. EL COMPUESTO ß-L NUCLEOSIDO 3'-O-SUSTITUIDO ES UNA ß-L-2'-DESOXIPURINA DE FORMULA II DONDE R1 ES H, ALQUILO, CO-ALQUILO, CO-ARILO, CO-ALCOXIALQUILO, ENTRE OTROS; R2 ES ALQUILO, CO-ALQUILO, CO-ARILO, RESIDUO AMINOACIDO, MONO, DI, O TRIFOSFATO; Y ES OR3, NR3R4, SR3; X1 Y X2 SON H, ALQUILO, CO-ALQUILO, ENTRE OTROS; R3-R6 SON H, ALQUILO, DIALQUILAMINOALQUILENO DE PREFERENCIA DIMETILAMINOMETILENO, CO-ALQUILO ENTRE OTROS.I ADEMAS A COMPUESTOS DE B-L NUCLEOSIDO 3'-O-SUSTITUIDO TAL COMO B-L-2'-DESOXIPURINA, ß-L-2'-DESOXIADENOSINA, B-L-2'-DESO-GUANIDINA, B-L-2'-DESOXIINOSINA, B-L-2'-DESOXIPIRIMIDINA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE UNA INFECCION POR VIRUS DE HEPATITIS B
PE2001000584A 2000-06-15 2001-06-15 PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS PE20020216A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21210000P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
PE20020216A1 true PE20020216A1 (es) 2002-04-16

Family

ID=22789563

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000584A PE20020216A1 (es) 2000-06-15 2001-06-15 PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS

Country Status (27)

Country Link
EP (1) EP1296995B1 (es)
JP (1) JP4639032B2 (es)
KR (2) KR20030032967A (es)
CN (3) CN1900104A (es)
AP (1) AP1771A (es)
AR (1) AR035711A1 (es)
AT (1) ATE411332T1 (es)
AU (2) AU6692701A (es)
BR (1) BR0111732A (es)
CA (1) CA2413163C (es)
CZ (1) CZ2003122A3 (es)
DE (1) DE60136181D1 (es)
EA (1) EA005774B1 (es)
ES (1) ES2317912T3 (es)
IL (3) IL153379A0 (es)
MA (1) MA27126A1 (es)
MX (1) MXPA02012443A (es)
MY (1) MY141594A (es)
NO (1) NO20026001L (es)
NZ (2) NZ523632A (es)
OA (1) OA12384A (es)
PE (1) PE20020216A1 (es)
PL (1) PL360404A1 (es)
UY (1) UY26779A1 (es)
WO (1) WO2001096353A2 (es)
YU (1) YU94802A (es)
ZA (2) ZA200300168B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404639A1 (en) 2000-04-13 2001-10-25 Pharmasset, Ltd. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US7138376B2 (en) 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
CA2490191C (en) 2002-06-28 2010-08-03 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
RS114104A (sr) * 2002-06-28 2007-02-05 Idenix (Cayman) Limited, 2'i 3'-nukleozidni prolekovi za lečenje flaviviridae infekcija
DK1572095T3 (en) * 2002-09-13 2015-09-14 Novartis Ag BETA-L-2'-DEOXYNUCLEOTIDES FOR TREATMENT OF RESISTANT HBV STANDS AND COMBINATION THERAPIES
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
CA2509687C (en) 2002-12-12 2012-08-14 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
WO2004084453A2 (en) 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
US7595390B2 (en) 2003-04-28 2009-09-29 Novartis Ag Industrially scalable nucleoside synthesis
ES2906207T3 (es) 2003-05-30 2022-04-13 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
JP2007527396A (ja) 2003-06-30 2007-09-27 イデニクス(ケイマン)リミテツド β−L−2’−デオキシヌクレオシドの合成
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
CA2611151A1 (en) 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
BRPI0915173B8 (pt) 2008-06-11 2021-05-25 Agilent Technologies Inc compostos de nucleotídeos e nucleosídeos e método de sequenciamento de um ácido nucleico-alvo
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
TW201026716A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
AR094621A1 (es) 2010-04-01 2015-08-19 Idenix Pharmaceuticals Inc Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
KR102048274B1 (ko) 2011-09-13 2019-11-25 애질런트 테크놀로지스, 인크. 핵산 시퀀싱을 위하여 5-메톡시, 3'-oh 차단안된, 신속하게 광절단가능한 종료 뉴클레오티드 및 핵산 시퀀싱 방법
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
CN104144682A (zh) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 两个抗病毒化合物的联用制剂
KR102239196B1 (ko) 2013-08-27 2021-04-12 길리애드 파마셋 엘엘씨 2종의 항바이러스 화합물의 조합 제제
IL277725B2 (en) * 2018-04-12 2024-02-01 Modis Therapeutics Inc Pro-drugs of deoxynucleosides for the treatment of diseases resulting from an imbalance in the nucleotide reserves

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
SE505648C2 (sv) * 1996-08-30 1997-09-22 Scania Cv Ab Anordning vid ett fordon för monterbar anfästning av en förarplatsmodul
CN100482236C (zh) * 1998-08-10 2009-04-29 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β-L-2’-脱氧-核苷

Also Published As

Publication number Publication date
ATE411332T1 (de) 2008-10-15
OA12384A (en) 2006-04-17
JP2004533403A (ja) 2004-11-04
KR20030032967A (ko) 2003-04-26
KR20070048277A (ko) 2007-05-08
EA200300023A1 (ru) 2003-08-28
CN1452627A (zh) 2003-10-29
CA2413163C (en) 2008-11-18
NZ523632A (en) 2005-03-24
NO20026001L (no) 2003-02-12
CN101012259A (zh) 2007-08-08
BR0111732A (pt) 2003-06-24
ZA200404306B (en) 2005-06-15
EP1296995B1 (en) 2008-10-15
CA2413163A1 (en) 2001-12-20
AU6692701A (en) 2001-12-24
EA005774B1 (ru) 2005-06-30
IL153379A0 (en) 2003-07-06
AU2001266927B2 (en) 2006-12-14
JP4639032B2 (ja) 2011-02-23
NO20026001D0 (no) 2002-12-13
WO2001096353A3 (en) 2002-04-18
AP2003002713A0 (en) 2003-03-31
ZA200300168B (en) 2004-07-07
CN1900104A (zh) 2007-01-24
YU94802A (sh) 2006-03-03
MY141594A (en) 2010-05-14
CN1295242C (zh) 2007-01-17
PL360404A1 (en) 2004-09-06
CZ2003122A3 (cs) 2003-06-18
ES2317912T3 (es) 2009-05-01
IL178864A0 (en) 2007-03-08
DE60136181D1 (de) 2008-11-27
IL153379A (en) 2007-02-11
UY26779A1 (es) 2001-12-28
EP1296995A2 (en) 2003-04-02
WO2001096353A2 (en) 2001-12-20
AR035711A1 (es) 2004-07-07
NZ535246A (en) 2006-06-30
MXPA02012443A (es) 2004-09-10
AP1771A (en) 2007-08-23
MA27126A1 (fr) 2005-01-03

Similar Documents

Publication Publication Date Title
PE20020216A1 (es) PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS
RU2478104C2 (ru) Нуклеозидфосфорамидаты в качестве противовирусных агентов
BRPI0414176A (pt) inibidores de serina proteases, em particular hcv ns3-ns4a protease
RU2327701C2 (ru) Нуклеозидные производные и фармацевтическая композиция, обладающая антивирусной активностью в отношении hcv
ATE313550T1 (de) Beta-l-2'-deoxynukleoside für die behandlung von hepatitis b virus
RU2009123104A (ru) Арилфосфорамидаты нуклеозида и их применение в качестве противовирусных средств для лечения вирусного гепатита с
WO2000063364A3 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
PE20001072A1 (es) Antivirales derivados de purinas
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
AR035336A1 (es) Metodo para el tratamiento o profilaxis de una infeccion por el virus de hepatitis c
BR0110023A (pt) Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite
EA200300819A1 (ru) Производные нуклеозидов в качестве ингибиторов рнк-зависимой рнк вирусной полимеразы
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
DE60119968D1 (en) Hepatitis c tripeptid inhibitoren
BR0305259A (pt) Inibidores de hcv ns5b polimerase
AR031520A1 (es) Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
CO5231152A1 (es) Formulaciones plaguicidas que contienen tensoactivos de piliarilfenolfosfatoester alcoxilado y tensoactivo de lignosulfonato alcoxilado
RU2003134629A (ru) Соединения цефема
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
BR9915555A (pt) Composto, composição e uso de ß - l- (2' ou 3' -azido) - 2', 3' -didesóxi -5-flúor citosina para o tratamento de infecção por vìrus de hepatite b
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
NZ502837A (en) Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the DNA polymerase of hepatitis B virus (HBV)
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
EA200100711A1 (ru) Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция
AR042335A1 (es) Derivados de nucleosido antivirales

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed